VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024....
AbCellera Biologics is a biotechnology company built to discover new antibodies for other drugmakers. The stock has fallen more than 90% from its all-time high and by 57% from a peak it set last summe...
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024....
With the technology benchmark Nasdaq index encountering some choppy weather since April, speculators may want to consider undervalued Nasdaq stocks. Granted, it's always risky betting on enterprises t...
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, Chief Exec...
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.14 per share a year ago....
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2024 Business Results....
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies....
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024....
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at...